Affinity Asset Advisors, LLC
NEW YORK, NY · CIK 1773195 · 13F filing filed 2026-08-13
SEC-registered investment adviser since 2021 · limited liability company
- Assets managed$2.5bn
- Staff10 · 7 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds2 (1 hedge) · $2.5bn gross assets
- Websiteaffinityadv.com
- Form ADV · 2026-07-27SEC adviser record
- Legal entityAFFINITY ASSET ADVISORS, LLC (US)
$2.0bn
reported value
+19.9% vs Q1 2026
104positions
42.6%in top 10
19 new
33 added
28 reduced
10 sold out
vs Q1 2026
Options: 6 call positions ($112.6m notional), 3 put positions ($55.1m notional) – listed below, not included above.
Holdings, Q2 2026
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| ROIVANT SCIENCES LTD ROIV | $132.7m6.49% | Added +950.0k |
| APOGEE THERAPEUTICS INC COM | $131.0m6.41% | Reduced -297.9k |
| SPYRE THERAPEUTICS INC SYRE | $113.6m5.55% | Unchanged |
| XENON PHARMACEUTICALS INC XENE | $96.3m4.71% | Reduced -80.0k |
| ERASCA INC ERAS | $96.2m4.70% | Reduced -100.0k |
| INSMED INC INSM | $69.3m3.39% | Added +170.0k |
| PRAXIS PRECISION MEDICINES I PRAX | $61.9m3.03% | Added +15.0k |
| ALKERMES PLC ALKS | $58.9m2.88% | Reduced -225.0k |
| ORUKA THERAPEUTICS INC ORKA | $56.2m2.75% | Added +90.3k |
| ANAPTYSBIO INC ANAB | $55.8m2.73% | Reduced -113.9k |
| AVALO THERAPEUTICS INC AVTX | $53.6m2.62% | Added +1.6m |
| CYTOKINETICS INC CYTK | $46.9m2.29% | Reduced -150.5k |
| REVOLUTION MEDICINES INC RVMD | $46.8m2.29% | Added +150.0k |
| ABIVAX SA ABVX | $44.0m2.15% | Reduced -75.0k |
| FIRST TRACKS BIOTHERAPEUTICS TRAX | $40.9m2.00% | New |
| DIANTHUS THERAPEUTICS INC DNTH | $39.0m1.91% | Added +50.0k |
| SUTRO BIOPHARMA INC STRO | $38.9m1.90% | Added +103.0k |
| NUVALENT INC COM | $34.0m1.66% | Reduced -25.0k |
| TREVI THERAPEUTICS INC TRVI | $33.6m1.64% | Reduced -200.0k |
| OVID THERAPEUTICS INC OVID | $27.3m1.33% | Reduced -491.8k |
| LEXEO THERAPEUTICS INC LXEO | $27.0m1.32% | Added +757.4k |
| CELLDEX THERAPEUTICS INC NEW CLDX | $26.0m1.27% | Added +200.0k |
| BELITE BIO INC BLTE | $25.4m1.24% | Added +100.0k |
| ENLIVEN THERAPEUTICS INC ELVN | $25.4m1.24% | Reduced -86.9k |
| FORTE BIOSCIENCES INC FBRX | $24.3m1.19% | Added +133.5k |
| NURIX THERAPEUTICS INC NRIX | $23.5m1.15% | Unchanged |
| ALTO NEUROSCIENCE INC ANRO | $22.4m1.10% | Added +350.0k |
| MADRIGAL PHARMACEUTICALS INC MDGL | $21.5m1.05% | Reduced -15.0k |
| PROTAGONIST THERAPEUTICS INC PTGX | $21.1m1.03% | Unchanged |
| MINERALYS THERAPEUTICS INC MLYS | $20.2m0.99% | Unchanged |
| RELAY THERAPEUTICS INC RLAY | $19.6m0.96% | Added +650.0k |
| SAGIMET BIOSCIENCES INC SGMT | $19.3m0.94% | Added +1.6m |
| JADE BIOSCIENCES INC JBIO | $18.7m0.91% | Added +200.4k |
| COGENT BIOSCIENCES INC COGT | $17.4m0.85% | Reduced -300.0k |
| TRAVERE THERAPEUTICS INC TVTX | $17.0m0.83% | Unchanged |
| CULLINAN THERAPEUTICS INC CGEM | $15.9m0.78% | Added +94.5k |
| SAVARA INC SVRA | $15.5m0.76% | Unchanged |
| IDEAYA BIOSCIENCES INC IDYA | $14.9m0.73% | New |
| PERSPECTIVE THERAPEUTICS INC CATX | $14.4m0.70% | Added +1.1m |
| ODYSSEY THERAPEUTICS INC ODTX | $14.3m0.70% | New |
| COGENT BIOSCIENCES INC COGT 1.625 11.15.31 · principal | $13.7m0.67% | Added +4.0m |
| HELIX ACQUISITION CORP III HLXC | $13.3m0.65% | Unchanged |
| EQUILLIUM INC EQ | $13.1m0.64% | Added +2.9m |
| ESTABLISHMENT LABS HLDGS INC ESTA | $12.7m0.62% | Added +48.0k |
| CLIMB BIO INC CLYM | $12.7m0.62% | Added +272.0k |
| TEVA PHARMACEUTICAL INDS LTD SPONSORED ADS | $12.7m0.62% | Reduced -1.0m |
| VERADERMICS INC MANE | $12.3m0.60% | Added +30.0k |
| ARROWHEAD PHARMACEUTICALS IN ARWR | $12.2m0.60% | Reduced -50.0k |
| OMEROS CORP OMER 9.5 06.15.29 · principal | $12.2m0.60% | Unchanged |
| TAYSHA GENE THERAPIES INC TSHA | $11.9m0.58% | Added +750.0k |
| DAMORA THERAPEUTICS INC COM NEW | $11.1m0.54% | Reduced -25.0k |
| EUPRAXIA PHARMACEUTICALS INC EPRX | $10.9m0.53% | Added +61.0k |
| VERA THERAPEUTICS INC VERA | $10.7m0.52% | Unchanged |
| PROQR THRAPEUTICS N V PRQR | $10.3m0.50% | Added +3.1m |
| NEWAMSTERDAM PHARMA COMPANY NAMS | $9.3m0.46% | Unchanged |
| KORRO BIO INC KRRO | $9.3m0.46% | Unchanged |
| ANTERIS TECHNOLOGIES GLOBAL AVR | $9.0m0.44% | Unchanged |
| ZURA BIO LTD ZURA | $8.6m0.42% | Reduced -1.1m |
| UNIQURE NV QURE | $8.1m0.39% | New |
| ASCENDIS PHARMA A/S ASND | $8.0m0.39% | New |
| IBIO INC IBIO | $7.0m0.34% | Added +900.7k |
| GENERATE BIOMEDICINES INC GENB | $6.7m0.33% | Added +50.0k |
| TYRA BIOSCIENCES INC TYRA | $6.4m0.31% | Reduced -57.5k |
| SOL-GEL TECHNOLOGIES LTD SLGL | $6.3m0.31% | Added +49.9k |
| SAB BIOTHERAPEUTICS INC SABS | $5.9m0.29% | Added +950.0k |
| MACROGENICS INC MGNX | $5.6m0.27% | Added +716.6k |
| CRISPR THERAPEUTICS AG CRSP | $5.5m0.27% | Reduced -50.0k |
| NEWAMSTERDAM PHARMA COMPANY NAMSW | $5.3m0.26% | Unchanged |
| ASSEMBLY BIOSCIENCES INC ASMB | $5.2m0.26% | New |
| REZOLUTE INC RZLT | $5.2m0.25% | Reduced -547.6k |
| PRECISION BIOSCIENCES INC DTIL | $5.1m0.25% | Added +48.6k |
| HEMAB THERAPEUTICS HLDGS INC COAG | $5.1m0.25% | New |
| VIRIDIAN THERAPEUTICS INC VRDN | $4.6m0.22% | Unchanged |
| ARRIVENT BIOPHARMA INC AVBP | $4.3m0.21% | Reduced -50.0k |
| VERRICA PHARMACEUTICALS INC VRCA | $4.3m0.21% | Unchanged |
| COMPASS PATHWAYS PLC CMPS | $4.3m0.21% | Reduced -807.3k |
| MBX BIOSCIENCES INC MBX | $4.1m0.20% | Reduced -75.0k |
| RESEARCH ALLIANCE CORP III RACC | $4.0m0.19% | New |
| IMMUNOVANT INC IMVT | $3.9m0.19% | Unchanged |
| AMANAT ACQUISITION CORP AMAN | $3.8m0.19% | New |
| BIOHAVEN LTD BHVN | $3.7m0.18% | New |
| FAETH THERAPEUTICS INC FTH | $3.6m0.18% | New |
| KARYOPHARM THERAPEUTICS INC KPTI | $3.1m0.15% | Reduced -187.5k |
| ALECTOR INC ALEC | $3.0m0.15% | Added +1.0m |
| SPYGLASS PHARMA INC SGP | $2.9m0.14% | Reduced -118.4k |
| CRINETICS PHARMACEUTICALS IN CRNX | $2.8m0.14% | Unchanged |
| OAKTREE ACQUISITION CORP III OACCU | $2.8m0.13% | Unchanged |
| CELCUITY INC CELC 0.25 08.01.32 · principal | $2.3m0.11% | New |
| JATT II ACQUISITION CORP JATT | $2.3m0.11% | New |
| NEUMORA THERAPEUTICS INC. NMRA | $1.8m0.09% | New |
| AMYLYX PHARMACEUTICALS INC AMLX | $1.8m0.09% | New |
| ADLAI NORTYE LTD ANL | $1.8m0.09% | Reduced -10.9k |
| SPRUCE BIOSCIENCES INC SPRB | $1.6m0.08% | New |
| EIKON THERAPEUTICS INC EIKN | $1.3m0.06% | New |
| ONKURE THERAPEUTICS INC OKUR | $1.1m0.05% | Unchanged |
| ENGENE THERAPEUTICS INC ENGN | $1.0m0.05% | New |
| X4 PHARMACEUTICALS INC XFOR | $677.1k0.03% | Unchanged |
| BOUNDLESS BIO INC BOLD | $625.0k0.03% | New |
| LENZ THERAPEUTICS INC LENZ | $568.0k0.03% | Unchanged |
| Q32 BIO INC QTTB | $353.9k0.02% | Unchanged |
Sold out since Q1 2026
| Security | Value then |
|---|---|
| CENTESSA PHARMACEUTICALS PLC | $55.6m1.4m shares |
| ARCELLX INC ACLX | $41.7m362.8k shares |
| TERNS PHARMACEUTICALS INC | $29.7m562.6k shares |
| ASCENDIS PHARMA A/S | $21.7m95.0k shares |
| BRIDGEBIO PHARMA INC BBIO | $11.1m150.0k shares |
| WAVE LIFE SCIENCES LTD 96663EUR | $10.2m1.4m shares |
| CELCUITY INC CELC 2.75 08.01.31 | $7.3m3.0m shares |
| ENGENE HOLDINGS INC | $4.2m610.4k shares |
| CORCEPT THERAPEUTICS INC CORT | $2.0m50.0k shares |
| KEZAR LIFE SCIENCES INC KZR | $1.7m229.1k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| MODERNA INC MRNA · Put | $35.0m500.0k shares | New |
| MODERNA INC MRNA · Call | $33.3m475.0k shares | Reduced |
| ARK ETF TR ARKG · Call | $31.5m750.0k shares | New |
| ELI LILLY & CO LLY · Call | $24.0m20.0k shares | New |
| OMEROS CORP OMER · Put | $13.4m1.4m shares | New |
| ALKERMES PLC ALKS · Call | $13.1m250.0k shares | New |
| UNIQURE NV QURE · Call | $9.2m200.0k shares | Reduced |
| EVOMMUNE INC EVMN · Put | $6.6m500.1k shares | New |
| SUMMIT THERAPEUTICS INC SMMT · Call | $1.5m100.0k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| IBIO INC IBIO · 13G · filed 2026-08-13 | 10.0%≈ $8.9m |
| KARYOPHARM THERAPEUTICS INC KPTI · 13G · filed 2026-05-14 | 8.6%≈ $20.3m |
| LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-13 | 8.4%≈ $31.1m |
| OVID THERAPEUTICS INC OVID · 13G · filed 2026-08-13 | 7.9%≈ $40.7m |
| SUTRO BIOPHARMA INC 13G · filed 2025-10-23 | 7.8% |
| HELIX ACQUISITION CORP III HLXC · 13G · filed 2026-05-14 | 7.0%≈ $13.3m |
| EQUILLIUM INC EQ · 13G · filed 2026-08-13 | 6.5%≈ $13.1m |
| SUTRO BIOPHARMA INC STRO · 13G · filed 2026-05-14 | 6.5%≈ $35.5m |
| NEXTCURE INC NXTC · 13G · filed 2026-08-13 | 6.4%≈ $438.5k |
| FIRST TRACKS BIOTHERAPEUTICS TRAX · 13G · filed 2026-08-13 | 5.8%≈ $40.9m |
| FORTE BIOSCIENCES INC FBRX · 13G · filed 2026-08-13 | 5.6%≈ $24.3m |
| AVALO THERAPEUTICS INC AVTX · 13G · filed 2026-08-13 | 5.5%≈ $53.6m |
| VERRICA PHARMACEUTICALS INC VRCA · 13G · filed 2026-01-29 | 5.5%≈ $5.4m |
| AMANAT ACQUISITION CORP AMAN · 13G · filed 2026-08-13 | 5.0%≈ $3.8m |